Clinical breast cancer最新文献

{"title":"A Radiomic and Clinical Data-Based Risk Model for Malignancy Prediction of Breast BI-RADS 4A Microcalcifications.","authors":"Nicole Brunetti, Cristina Campi, Michele Piana, Ilaria Picone, Caterina Vercelli, Oleksandr Starovatskyi, Giuseppe Rescinito, Simona Tosto, Alessandro Garlaschi, Massimo Calabrese, Alberto Stefano Tagliafico","doi":"10.1016/j.clbc.2025.01.006","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.01.006","url":null,"abstract":"<p><strong>Background: </strong>Mammography is the gold standard technique for early breast cancer screening, but it has a limited specificity for microcalcifications. Radiomics represents a promising tool for enhancing lesion risk stratification. This study aims to evaluate the reliability of radiomics in combination with clinical data to classify benign and malignant microcalcifications, potentially enhancing the standard radiological assessment and reducing the need for biopsies.</p><p><strong>Materials and methods: </strong>This study retrospectively analyzed patients with BI-RADS 4A microcalcifications who underwent mammography (MX) and vacuum-assisted breast biopsy (VABB) at our center from January 2019 to February 2023. About 104 radiomics features were extracted from a region of interest, manually defined on images. Clinical data from each patient were collected. Using the Tyrer-Cuzick Model, we classified patients according to the risk of developing breast cancer. Two logistic regression models, using clinical and radiomics data were trained to predict the pathological classification of breast calcifications.</p><p><strong>Results: </strong>A total of 167 calcification groups were included in the study. The final dataset was made of 14 radiomics features. The radiomics model alone achieved an AUC of 0.72 (95% CI, 0.61-0.33) while the model trained on clinical and radiomics features obtained AUC values of 0.81 (95% CI, 0.69-0.92).</p><p><strong>Conclusions: </strong>Our findings suggest that the integration of clinical data with radiomics has the potential to reduce unnecessary biopsies for BI-RADS 4A microcalcifications, leading to more targeted and personalized patient care.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply on: Regina Elena Institute (R.E.I.) Protocol for Breast Implant Salvage: Preliminary Results","authors":"Anna Scarabosio ,&nbsp;Alberto Pagotto ,&nbsp;Glenda Giorgia Caputo","doi":"10.1016/j.clbc.2025.01.010","DOIUrl":"10.1016/j.clbc.2025.01.010","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 3","pages":"Pages e326-e327"},"PeriodicalIF":2.9,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of CALM Intervention on Negative Emotions and Sleep Quality in Patients Undergoing Endocrine Therapy for Breast Cancer.","authors":"Yingxue Jia, Chen Gan, Jiaying Chai, Runze Huang, Anlong Li, Han Ge, Xinyi Zheng, Lijun Liu, Jian Xu, Ling Cheng, Huaidong Cheng","doi":"10.1016/j.clbc.2025.01.007","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.01.007","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding the Article “Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care”","authors":"Akshaya viswanathan,&nbsp;Rajesh Kanna Gopal,&nbsp;Pitchaipillai Sankar Ganesh","doi":"10.1016/j.clbc.2025.01.004","DOIUrl":"10.1016/j.clbc.2025.01.004","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 3","pages":"Pages e324-e325"},"PeriodicalIF":2.9,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on the Differentiation of Infiltrating Breast Cancer Molecular Subtypes Based on Ultrasound Radiomics.","authors":"Hanqin Liu, Han Xia, Xiaoxiao Yin, Aiping Qin, Wen Zhang, Shuang Feng, Jing Jin","doi":"10.1016/j.clbc.2025.01.005","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.01.005","url":null,"abstract":"<p><strong>Objective: </strong>To establish and validate a 2-dimensional ultrasound (US) radiomics model for the noninvasive preoperative differentiation of various molecular subtypes of infiltrating breast cancer (IBC).</p><p><strong>Methods: </strong>A retrospective analysis of 210 female patients diagnosed with IBC through surgical operation or needle biopsy pathology at our hospital between May 2019 and February 2024 was conducted. Relevant data were collected to establish predictive models for different molecular subtypes of IBC.</p><p><strong>Results: </strong>Based on 5936 US radiomics features, 39, 25 and 19 optimal features were identified for the differentiation of luminal versus nonluminal types, luminal A versus luminal B types and human epidermal growth factor receptor 2 (HER2) overexpression versus triple-negative (TN) IBC subgroups, respectively. The corresponding areas under the curve for the training and validation sets were 0.901 and 0.752 (luminal vs. nonluminal), 0.931 and 0.773 (luminal A vs. luminal B) and 0.962 and 0.842 (HER2 overexpression vs. TN), respectively, indicating robust discriminatory performance of these models for different pathological molecular subtypes of IBC.</p><p><strong>Conclusion: </strong>A radiomics model based on US images is capable of effectively differentiating between various molecular subtypes of IBC prior to surgery, holding promise in assisting medical professionals in crafting tailored diagnostic and therapeutic strategies.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Information on Breast Cancer Surgery on YouTube®","authors":"Louise Cousins,&nbsp;Lynn Darragh,&nbsp;Barry Kerr","doi":"10.1016/j.clbc.2025.01.003","DOIUrl":"10.1016/j.clbc.2025.01.003","url":null,"abstract":"<div><h3>Introduction</h3><div>The quality, reliability and accuracy of health-related videos available online is controversial. Research has examined YouTube® in terms of reconstruction, breast screening, radiotherapy, postoperative arm exercises and mastectomy. The aim of this study is to assess YouTube® as a form of health information on breast cancer surgery/operation.</div></div><div><h3>Methods</h3><div>YouTube® was searched using the terms ``breast cancer surgery'' and ``breast cancer operation.'' Video data was recorded including time since upload, video length, viewer engagement, content and upload source. The quality, accuracy and educational usefulness of videos were analyzed using 3 online quality assessment tools by a single clinician. Gender and ethnic representation of the patient was recorded.</div></div><div><h3>Results</h3><div>About 48 videos were reviewed, 62% of videos uploaded from a Healthcare source and the most common video category was post-op complications/issues (25% of videos). Engagement was highest for videos uploaded from individuals which showed 54.36 “likes”/day and 6.9 comments/day. Healthcare sourced videos were higher quality. The mean DISCERN score for healthcare videos was 34.33 ± 11.44 compared with non-Healthcare scoring 26.33 ± 8.35 (<em>P</em> = .013). 100% of videos referenced females with breast cancer only. 71% showed only white/Caucasian patients/models.</div></div><div><h3>Discussion</h3><div>In line with previous research, this study showed Healthcare sourced videos were of higher quality. Quality of life information hasn't been reported elsewhere however this study found it was limited and of poor quality. While high levels of misleading information have been reported elsewhere, this study highlighted only 4% as misleading/unsafe.</div></div><div><h3>Conclusions</h3><div>Healthcare professional interaction with YouTube® should be encouraged and empowered, in order to educate with the delivery of high-quality health information which is reliable and valid. Quality of life content should be considered by healthcare professionals. This study highlights a paucity of videos on male breast cancer, and suggests the need for more ethnically diverse patient representation on breast cancer surgery/operation on YouTube.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 3","pages":"Pages 291-298"},"PeriodicalIF":2.9,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Adjuvant Capecitabine in Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Treatment: A Real-World Evidence Study in Korea.","authors":"Min Jeong Kim, Hyo Jung Kim, Ji-Yeon Kim, Junghoon Shin, Yeon Hee Park","doi":"10.1016/j.clbc.2024.12.019","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.12.019","url":null,"abstract":"<p><strong>Background: </strong>Residual disease after neoadjuvant chemotherapy (NAC) has important role in triple negative breast cancer (TNBC). The CREATE-X study demonstrated a survival benefit from adjuvant capecitabine (adjC) in breast cancer patients, especially for TNBC populations. Because the landscape of early TNBC treatment has been changing rapidly, an optimal adjuvant strategy for real-world practice is needed. We evaluated the effectiveness of adjC in TNBC patients with residual disease after NAC.</p><p><strong>Method: </strong>We used de-identified, anonymous data from an institutional clinical data warehouse to retrospectively analyze 934 TNBC patients who received NAC between 2017 and 2023. Among them, 405 patients received at least 1 cycle of adjC, and 77 received no adjuvant treatment. The primary outcomes of the study were distant-disease free survival (DDFS) rate and overall survival (OS) rate at 3 years. The secondary outcomes were subgroup analyses and Cox regression analyses of survival outcomes.</p><p><strong>Result: </strong>The median follow up period was 34.3 months (range 1.8-71.5). The DDFS rate at 3 years was higher in the capecitabine group: 86.3% of the capecitabine group and 74.4% of the no adjuvant group (P = .019). The OS rates at 3 years were 93.3% and 83.8%, respectively (P = .032). Subgroup analyses indicated a greater benefit from adjC in patients aged 50 years or older and those who received platinum-based NAC, both in terms of DDFS and OS.</p><p><strong>Conclusion: </strong>Our study showed that adjC was more effective than no adjuvant treatment for TNBC patients with residual disease in terms of DDFS and OS.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Added Value of Physical Examination for Breast Cancer Recurrence Detection in Women: A Systematic Review.","authors":"L T H Godding, A Dekker-Klaassen, J H Volders, M van Hezewijk, E J M Siemerink, D van Uden, J Veltman, A H Eijkelboom, S Siesling","doi":"10.1016/j.clbc.2024.12.014","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.12.014","url":null,"abstract":"<p><p>As the number of curatively treated breast cancer patients grows and the burden on healthcare increases, effective use of methods to detect recurrences is becoming more important. This systematic review aims to examine the added value of physical examination (PE) in addition to mammography for breast cancer recurrence detection. PubMed, Web of Science, and Scopus were searched. Observational studies including women with a primary diagnosis of invasive or in situ breast cancer without metastases, which reported method of detection for locoregional recurrences (LRRs), and in which PE was defined as examination by a healthcare provider in an asymptomatic patient were included. Quality was assessed using the ROBINS-1 tool. Nine studies were included with data on 14,406 women, 613 LRRs and 349 secondary primary breast cancers. Of the total LRRs, 46.3% were detected by patients, 23.3% by mammography, and 14.8% by PE. PE detected 11% of the LRRs in patients who had breast conserving surgery and 28% of the LRRs in mastectomy patients. PE detected 7.1% of the contralateral breast cancers and 18.8% of ipsilateral lymph node recurrences, compared to 43.9% and 29.2% by mammography. PE detected a LRR in 0.6% of the patients (91/14,406) and mammography in 1.5% of the patients (143/9614). For detection of breast cancer recurrences, PE is of limited added value alongside mammography and self-detection, although it seems more beneficial for mastectomy patients. Further research is required to determine the effectiveness of the most efficient interval for PE across different patient groups.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Short- and Long-Term Survival in Metastatic HER2-Positive Breast Cancer.","authors":"José P Leone, Ruth Moges, Julieta Leone, Carlos T Vallejo, Heather A Parsons, Michael J Hassett, Nancy U Lin","doi":"10.1016/j.clbc.2025.01.002","DOIUrl":"10.1016/j.clbc.2025.01.002","url":null,"abstract":"<p><strong>Background: </strong>We sought to evaluate prognostic factors in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and their relationship with short- and long-term overall survival (OS).</p><p><strong>Methods: </strong>Using the Surveillance, Epidemiology, and End Results (SEER) database, we evaluated patients with de novo HER2-positive MBC diagnosed from 2010 to 2018. Univariate analyses were performed to determine effect of each variable on OS. Significant variables were included in a multivariate Cox model for OS. Univariate and multivariate logistic regression were used to evaluate the association of each variable with short- (<2 years) and long- (≥5 years) term OS.</p><p><strong>Results: </strong>Overall, 5576 patients were included. Median follow up was 48 months (interquartile range 25-73 months), and median OS was 41 months. The proportion alive at 2, 5, and 8 years was 63.3% (95% confidence interval [CI] 62.0%-64.7%), 37.8% (95% CI, 36.2%-39.4%), and 26.8% (95% CI, 24.8%-28.9%), respectively. Factors associated with short-term OS were older age; Black race; nonductal nonlobular; brain, liver, or lung metastases; estrogen/progesterone receptor (ER/PR)-negative disease, and lower income (all P < .04). Number of metastatic organ sites was not significant. Factors associated with long-term OS were younger age, White race, fewer metastatic organ sites, ER/PR-positive disease, and higher income (all P < .02). Specific organ sites were not significant.</p><p><strong>Conclusions: </strong>In this cohort with de novo HER2-positive MBC, OS improved significantly over the study period. We identified patient-specific and tumor-specific factors that were associated with short- and long-term survival in HER2-positive MBC.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Baseline Comorbidities and Performance Status on HER2-Targeted Therapy Outcomes.","authors":"Amir Reza Akbari, Benyamin Alam","doi":"10.1016/j.clbc.2024.12.017","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.12.017","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}